Biogen Inc. (BIIB) Business Profile

What it does

Biogen is a global biopharmaceutical company that discovers, develops and sells medicines for serious diseases. Founded in 1978 and headquartered in Cambridge, it is led by President and Chief Executive Officer Christopher A. Viehbacher.

Its medicines treat people with multiple sclerosis (MS), a disease that disrupts signals along nerve cells. They include TYSABRI, VUMERITY, TECFIDERA, AVONEX and PLEGRIDY. Biogen also sells SPINRAZA for spinal muscular atrophy, SKYCLARYS for Friedreich’s ataxia and QALSODY for a genetic form of amyotrophic lateral sclerosis. These are rare diseases that affect the nervous system or muscles.

Biogen collaborates with Eisai on LEQEMBI for Alzheimer’s disease and with Supernus on ZURZUVAE for postpartum depression. It also sells biosimilars: medicines made to be similar to existing biological drugs. Its rights under a Genentech collaboration provide financial interests in several other therapies, including OCREVUS and RITUXAN.

Since acquiring Apellis, Biogen has added SYFOVRE and EMPAVELI to its commercial portfolio. It also researches potential medicines internally and through collaborations and acquisitions, with a pipeline spanning neurology, specialized immunology and rare diseases.

How it makes money

Biogen earns revenue from selling its own medicines, commercializing biosimilars and participating in collaboration arrangements. Its products address MS, rare diseases and other conditions; the company also has financial rights to therapies commercialized through its Genentech collaboration.

The LEQEMBI arrangement with Eisai has a distinct economics structure: Biogen’s Alzheimer’s collaboration revenue consists of its 50.0% share of net LEQEMBI product revenue and cost of sales, including royalties. TYSABRI and SPINRAZA each accounted for more than 10.0% of total revenue in each of the years ended December 31, 2025, 2024 and 2023.

Biogen’s medicines can be used over extended periods, though demand depends on patients starting and continuing treatment. For example, SPINRAZA’s higher-dose regimen includes maintenance doses. Biogen said the third quarter of 2026 benefited from one-time transition doses as patients moved to that regimen; it expects dosing patterns to normalize as the conversion group matures.

Product prices and sales also depend on coverage and reimbursement. Governments, health plans and other payors can seek discounts or impose access restrictions. Biogen said tighter Medicare Part D formulary management affected VUMERITY revenue in the third quarter of 2026.

In Q3 2026, total revenue was $2.8 billion, including $2 billion of core pharmaceutical revenue. SYFOVRE and EMPAVELI together contributed $243 million in that quarter.

Customers and how it sells

Biogen’s medicines reach patients through healthcare professionals, including physicians who prescribe them and practitioners who administer certain drugs. Access also depends on payors: governments, private health plans and other organizations determine coverage or reimbursement, while some seek discounts or restrictions on particular medicines.

Biogen operates across the U.S. and international markets. Major MS markets include the U.S. and several European countries. LEQEMBI’s major markets include the U.S., China, Japan and South Korea. For SPINRAZA, major markets include the U.S., Brazil and several European countries; SKYCLARYS is marketed in the U.S. and countries including France, Germany and Italy.

LEQEMBI received European Union approval for a defined group of patients with early Alzheimer’s disease in 2025. Biogen and Eisai are partners in its commercialization. Biogen said patients could access reimbursement for the LEQEMBI iClick launch through a medical exception process in the third quarter of 2026, and it expects broader reimbursement to affect uptake.

Biogen had 7,500 employees in FY2025.

Suppliers and costs

Biogen uses both its own facilities and outside manufacturers. Third parties principally make the active ingredients and finished products for its small-molecule medicines, including VUMERITY and SKYCLARYS, as well as the finished drug product for its large-molecule medicines.

Its operational biologics plant in Solothurn, Switzerland, is approved to manufacture LEQEMBI and TYSABRI. Biogen also invests in its existing manufacturing facilities in RTP. Certain starting materials for SKYCLARYS rely on a single supplier in China, although the product’s manufacturing process is primarily conducted in the U.S. Switching suppliers can require regulatory approvals and add costs or delays.

Research and development, selling and administrative activities, manufacturing, and payments under acquisition and collaboration agreements all contribute to costs. Biogen said combined non-GAAP research and development and selling, general and administrative expense increased 27% year over year in Q3 2026, primarily reflecting Apellis expenses and investment in late-stage programs and launches. Unused manufacturing capacity can also result in charges.

Competitive position

Biogen competes with other pharmaceutical and biotechnology companies developing and selling treatments for the same diseases. Competition can turn on efficacy, safety, convenience, delivery, reimbursement and price. The named competing medicines include Kisunla in Alzheimer’s disease and Zolgensma in spinal muscular atrophy; no specific competitor companies are identified for those medicines.

Generic TECFIDERA products have entered North America, Brazil and certain European countries at discounted prices. They have significantly reduced TECFIDERA revenue, and Biogen expects further decline. A TYSABRI biosimilar was approved in the U.S. and the EU in 2023; Biogen expects it to continue to affect TYSABRI sales.

Biogen’s established products and relationships with physicians and patients can help it reach users. Its research, manufacturing and commercial capabilities support drug development and launches. Patents and other proprietary rights can also protect products, although Biogen’s European patent related to TECFIDERA was revoked in 2025.

Our reading: The existing portfolio and commercial relationships provide a basis for reaching patients, but their protection is limited when lower-priced alternatives enter. Our reading: Intellectual property can support exclusivity, but the TECFIDERA experience shows that protection can be lost.

Growth opportunities

Biogen’s longer-term growth plans depend on developing and launching new medicines, adding uses for existing products, maintaining intellectual-property rights and executing external deals. The acquisition of Apellis added SYFOVRE and EMPAVELI; Biogen targets at least $250 million of annualized cost synergies by the end of 2027.

The company is also pursuing wider use of existing medicines. In Q3 2026, SPINRAZA revenue benefited from patients moving to the higher-dose regimen, while LEQEMBI in-market revenue grew year over year. Biogen expects broader reimbursement to influence uptake of LEQEMBI iClick.

Its pipeline includes felzartamab, an investigational medicine being studied in kidney conditions including antibody-mediated rejection after transplantation. Biogen estimates that approximately 11,000 patients have antibody-mediated rejection, while noting that not all would receive a product. It has also partnered with Stoke to develop zorevunersen for Dravet syndrome, a rare genetic epilepsy.

Biogen is developing litifilimab for lupus and has a funding arrangement with Royalty Pharma for the program. Its research collaborations include work on oral compounds for immunological conditions and RNA interference therapies for central nervous system diseases. Clinical success and regulatory approval remain necessary before investigational programs can be commercialized.

Structural risks

• Product competition: Generic and biosimilar versions can reduce both prices and sales volumes. Biogen expects generic TECFIDERA competition and a TYSABRI biosimilar to continue affecting those products.
• Pricing and reimbursement: Government pricing measures and private payors’ coverage restrictions, discounts or rebates can affect sales. LEQEMBI and SKYCLARYS depend in part on obtaining and maintaining adequate reimbursement.
• Clinical and regulatory outcomes: Successful early or late-stage trials do not ensure later trial success, approval or commercial viability. Regulators may also require additional testing or reject changes to approved products.
• Manufacturing and supply: Production is complex and regulated, and Biogen relies on third parties and some single-source providers. Supply disruptions or the need to qualify alternatives can cause added costs or delays.
• Collaborator dependence: Biogen may not control the resources partners devote to shared programs. Disputes, changes in partners’ priorities or disruptions at collaborators can affect development, manufacturing or commercialization.
• Product concentration: TYSABRI and SPINRAZA each represented more than 10.0% of total revenue in each of the years ended December 31, 2025, 2024 and 2023.

Bottom line

Our reading

Biogen combines an established neurological-disease business with newer medicines, collaborations and a pipeline that still needs clinical and regulatory success (item1; item7). Its commercial portfolio has broadened through Apellis, but generic and biosimilar competition, reimbursement and reliance on partners remain important exposures (call_prepared; item7; item1a).